Evogene Ltd. (TLV:EVGN)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 16.19M -52.8% |
| Revenue (ttm) | 5.82M -72.7% |
| Net Income | -37.16M |
| EPS | -4.32 |
| Shares Out | 10.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,631 |
| Open | 145.00 |
| Previous Close | 155.50 |
| Day's Range | 135.00 - 155.20 |
| 52-Week Range | 115.10 - 478.70 |
| Beta | 0.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses... [Read more]
Financial Performance
In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.
Financial numbers in USD Financial StatementsNews
Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation
Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation
Evogene, BCDD announces strategic joint initiative
Evogene (EVGN) and the Blavatnik Center for Drug Discovery, BCDD, at Tel Aviv University announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation...
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities REHOVOT, ISRAEL and TEL AVIV,...
Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud
Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud
Evogene achieves integration of agentic systems with ChemPass AI platform
Evogene (EVGN) announced the successful completion of a significant milestone in its second collaboration with Google (GOOG) Cloud. This milestone marks the integration of agentic computational system...
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing...
Evogene Slides: Company presentation
Evogene has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry s...
Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results
Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results
Evogene says Phase 1 clinical study of BMC128 met primary endpoint
Evogene (EVGN) announced the successful completion of the first-in-human Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in co...
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a p...
Evogene price target lowered to $2.15 from $2.25 at Alliance Global
Alliance Global lowered the firm’s price target on Evogene (EVGN) to $2.15 from $2.25 and keeps a Buy rating on the shares. Evogene reported Q1 results that were within the…
Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected
Miss Across Metrics. Evogene Ltd. (NASDAQ:EVGN) delivered disappointing Q1 2026 results that fell short of Wall Street expectations, reporting a loss per sh... The post Evogene Q1 2026 Loss Deepens: -...
Evogene Earnings Call Transcript: Q1 2026
Q1 2026 saw a sharp revenue decline and higher net loss, driven by lower Casterra sales and increased financing expenses. Strategic focus remains on AI-driven pharma and ag chemical pipelines, with new collaborations and internal R&D progress.
Evogene Earnings release: Q1 2026
Evogene released its Q1 2026 earnings on May 20, 2026, summarizing the period's financial results.
Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation
Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation
Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year
Reports Q1 revenue $300,000 vs. $2.3M last year. As of March 31, Evogene (EVGN) held consolidated cash, cash equivalents, and short-term bank deposits of approximately $13.1M. The consolidated cash us...
Evogene Reports First Quarter 2026 Financial Results
Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry spe...
Evogene to Present at the 24th Schrödinger European User Group Meeting
Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry spe...
Evogene Schedules First Quarter 2026 Financial Results Release
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, spec...
Evogene price target raised to $2.25 from $1.75 at Alliance Global
Alliance Global analyst Scott Henry raised the firm’s price target on Evogene (EVGN) to $2.25 from $1.75 and keeps a Buy rating on the shares. The company has pivoted its
Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price
Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price
Evogene receives Nasdaq minimum bid price notification
Evogene (EVGN) received a letter from Nasdaq indicating that the company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the cclosing bid price for its ordinary shares has
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative desig...
Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock
Today, castor oil is a premium sustainable industrial feedstock for bio-based products REHOVOT, Israel, March 31, 2026 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), a developer of high-yield castor s...